Drugs in Dev. Infections and Infectious Diseases
Phase III
South Korea 
Lead Product(s) : PCV21 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Sanofi Begins Phase 3 PCV21 Program, Expands Pneumococcal Vaccine Collaboration
Details : The collaboration aims to develop, license, and commercialize GBP410 (PCV21 vaccine) for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease.
Product Name : GBP410
Product Type : Vaccine
Upfront Cash : $52.0 million
December 23, 2024
Lead Product(s) : PCV21 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine Recombinant, Adjuvanted,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA’s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine
Details : Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.
Product Name : Skycovion
Product Type : Vaccine
Upfront Cash : Inapplicable
August 20, 2022
Lead Product(s) : COVID-19 Vaccine Recombinant, Adjuvanted,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regdanvimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Celltrion Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59)
Details : Top-line results also showed CT-P59 to have a positive safety profile, with no clinically meaningful differences between patients treated with CT-P59 (40mg/kg) and placebo-treated patients.
Product Name : Regkirona
Product Type : Antibody
Upfront Cash : Inapplicable
June 14, 2021
Lead Product(s) : Regdanvimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regdanvimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Starts Rolling Review of Celltrion Antibody Regdanvimab for Covid-19 Share
Details : Regdanvimab is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure (called an antigen).
Product Name : Regkirona
Product Type : Antibody
Upfront Cash : Inapplicable
February 24, 2021
Lead Product(s) : Regdanvimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NVX-COV2373,Matrix-m1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : SK Bioscience will add significant production capacity under this new agreement. Novavax recently reported positive interim efficacy results for the NVX-CoV2373 in an ongoing Phase 3 trial in the U.K and is also currently conducting a Phase 3 trial in th...
Product Name : Nuvaxovid
Product Type : Vaccine
Upfront Cash : Undisclosed
February 15, 2021
Lead Product(s) : NVX-COV2373,Matrix-m1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Reset All
